北大醫學部-諾輝健康(6606.HK)聯合啟動中國泛癌種早篩早診隊列PANDA研究項目
格隆匯11月1日丨北京大學醫學部與諾輝健康-B(6606.HK)今日舉行中國泛癌種早篩早診隊列PANDA研究項目(PANDA)啟動和聯合實驗室揭牌儀式。中國工程院院士、北京大學常務副校長、醫學部主任喬傑教授和諾輝健康董事長兼CEO朱葉青先生出席活動並致辭。

據悉,該研究項目是全球首個覆蓋DNA、RNA和蛋白質全維度以實現液體活檢泛癌種篩查和早期診斷的突破式創新。研究通過對血漿遊離DNA、RNA和蛋白質的大規模鑑定,發現具備高診斷性能的癌症診斷標誌物,結合大數據挖掘和機器學習,開發能夠早期診斷中國高發癌症的檢測技術和算法。諾輝健康計劃6年完成PANDA項目,總投入預計超過2億元人民幣,納入5萬名受試者。
“此次科研合作是我們在中國高發癌症預防的攻堅之戰,也是北大人鋭意創新、回報社會和人民的職責所在。”喬傑院士在致辭中講到,“PANDA項目將建設國際一流水平的聯合實驗室,打造一支研發的‘國家隊’,開展紮實嚴謹的臨牀試驗,推動中國早日實現高發癌症的可防可治。”
“諾輝健康的三位聯合創始人都畢業於北京大學生命科學院。在北大醫學辦學110週年之際,我們以此次簽約感恩母校的培養,也致敬歷屆北大人對創新的不懈追求。”朱葉青表示,“如果把腫瘤早篩早診的研發比喻為登山比賽,一管血實現多個高發癌症的早篩早診就是全球研究者攻堅的‘珠穆朗瑪’。當其他同行集中於血漿遊離DNA甲基化探索的時候,我們將和喬院士及北大醫學部開闢新的方向。我們有信心加入這個比賽,也對登頂的時刻充滿期待。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.